相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP)receptor antagonistGIP(3-30)NH2onGIPactions in humans
Laerke Smidt Gasbjerg et al.
DIABETES OBESITY & METABOLISM (2021)
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Mechanisms controlling pancreatic islet cell function in insulin secretion
Jonathan E. Campbell et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2021)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
K. El et al.
SCIENCE ADVANCES (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial
Domenica Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
990-P: Use of Glucose-Lowering Agents According to Cardiovascular Risk Factors in People with T2D and with or without CVD in the CAPTURE Study
GUILLERMO DIEUZEIDE et al.
DIABETES (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A. Killion et al.
ENDOCRINE REVIEWS (2020)
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Laerke S. Gasbjerg et al.
PEPTIDES (2020)
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes
Natasha C. Bergmann et al.
DIABETES CARE (2020)
GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals
Laerke S. Gasbjerg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
In the rat pancreas, somatostatin tonically inhibits glucagon secretion and is required for glucose-induced inhibition of glucagon secretion
Stella F. S. Xu et al.
ACTA PHYSIOLOGICA (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Elizabeth A. Killion et al.
NATURE COMMUNICATIONS (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Natasha C. Bergmann et al.
DIABETOLOGIA (2019)
Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies
Olivia M. Farr et al.
DIABETES OBESITY & METABOLISM (2019)
The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review
Amanda Brunchmann et al.
PHYSIOLOGY & BEHAVIOR (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
Laerke S. Gasbjerg et al.
DIABETES (2019)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr A. Mroz et al.
MOLECULAR METABOLISM (2019)
Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications
Jens J. Holst et al.
COMPREHENSIVE PHYSIOLOGY (2019)
Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors
Maria Buur Nordskov Gabe et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Insulin Secretion Depends on Intra- islet Glucagon Signaling
Berit Svendsen et al.
CELL REPORTS (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia
Colleen M. Craig et al.
DIABETOLOGIA (2017)
The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Anne Orgaard et al.
DIABETOLOGIA (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
Evidence of Extrapancreatic Glucagon Secretion in Man
Asger Lund et al.
DIABETES (2016)
Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes
Angus G. Jones et al.
DIABETES CARE (2016)
N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor
L. S. Hansen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the G alpha(q) pathway
Aiysha Thompson et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect
Stephanie Sisley et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation
Chen Varol et al.
JOURNAL OF IMMUNOLOGY (2014)
A Naturally Occurring GIP Receptor Variant Undergoes Enhanced Agonist-Induced Desensitization, Which Impairs GIP Control of Adipose Insulin Sensitivity
Sameer Mohammad et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Su-Jin Kim et al.
PLOS ONE (2012)
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
Asger Lund et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2011)
Glucose-Dependent Insulinotropic Polypeptide A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
Mikkel Christensen et al.
DIABETES (2011)
GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
Nikolaos Mentis et al.
DIABETES (2011)
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Meena Asmar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis
T. Edholm et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2010)
Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas
J. de Heer et al.
DIABETOLOGIA (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Case report: Somatostatin producing teratoma, causing rapidly alternating extreme hyperglycemia and hypoglycemia, and ovarian somatostatinoma
G Gregersen et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients
T Vilsboll et al.
DIABETES (2001)
分享论文
